<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023292</url>
  </required_header>
  <id_info>
    <org_study_id>2019-KY-051</org_study_id>
    <secondary_id>ChiCTR1900024427</secondary_id>
    <nct_id>NCT04023292</nct_id>
  </id_info>
  <brief_title>Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer</brief_title>
  <official_title>Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can promote proliferation of tumor cells in hormone receptors&#xD;
      (HR)-positive breast cancer. The standard therapy of Luminal subtypes is endocrine therapy,&#xD;
      which can influence proliferation of tumor cells by blocking the use of estrogen by cancer&#xD;
      cells or lowering the amount of estrogen the body makes. Thus, markers of proliferation are&#xD;
      candidate markers of efficacy after short-term (e.g., 2 weeks or 4 weeks) preoperative&#xD;
      hormone therapy. Ki-67 is most commonly used among these markers. In contrast to the absolute&#xD;
      value, the degree of Ki-67 changes which consider the baseline values would be better to&#xD;
      reflect the sensitivity of therapy. It is not yet known whether the degree of Ki-67 changes&#xD;
      after 2 weeks or 4 weeks presurgery endocrine therapy is different and which interval is more&#xD;
      suitable to assess therapy sensitivity.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying to compare the degree of Ki-67 changes&#xD;
      after 2 weeks or 4 weeks preoperative endocrine therapy and to determine a more appropriate&#xD;
      interval to assess hormone therapy sensitivity in women who are undergoing surgery for&#xD;
      HR-positive, Human epidermal growth factor receptor 2 (HER2)-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Pre-treatment to Post-treatment in Ki-67 Labelling Index</measure>
    <time_frame>2 weeks or 4 weeks endocrine treatment before surgery</time_frame>
    <description>Ki-67 labelling index is calculated as the percentage of cells with Ki-67-positive nuclear immunostaining as measured by immunohistochemistry (IHC). Range 0-100. Percentage change from pre-treatment to post-treatment=[(Ki-67post - Ki-67pre)/Ki-67pre]x100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>5 years post-randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years post-randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm I (2 weeks preoperative endocrine therapy))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (4 weeks preoperative endocrine therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.</description>
    <arm_group_label>Arm I (2 weeks preoperative endocrine therapy))</arm_group_label>
    <other_name>tamoxifen, Letrozole, Anastrazole, Exemestane, etc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.</description>
    <arm_group_label>Arm II (4 weeks preoperative endocrine therapy)</arm_group_label>
    <other_name>tamoxifen, Letrozole, Anastrazole, Exemestane, etc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent.&#xD;
&#xD;
          2. Female aged between 18 and 70 years.&#xD;
&#xD;
          3. Pathologically diagnosed operable invasive breast cancer meeting the following&#xD;
             criterias:&#xD;
&#xD;
               -  Hormone receptor (HR)-positive: pathologically diagnosed estrogen receptor&#xD;
                  (ER)-positive and/or progesterone receptor (PR)-positive;&#xD;
&#xD;
               -  Human epidermal growth factor receptor 2 (HER2)-negative: FISH or&#xD;
                  immunohistochemistry (IHC).&#xD;
&#xD;
          4. WHO Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          5. Newly diagnosed breast cancer.&#xD;
&#xD;
          6. The important organ functions meet the following criterias:&#xD;
&#xD;
               -  WBC &gt;=3.0 x 10^9/L; Neutrophilic granulocytes &gt;=1.5Ã—10^9/L; Platelet &gt;=100 x&#xD;
                  10^9/L; Hb &gt;=9 g/dL;&#xD;
&#xD;
               -  Total bilirubin no more than 1.5 times the normal upper limit (ULN); AST and ALT&#xD;
                  no more than 1.5 times ULN; AKP no more than 2.5 times ULN;&#xD;
&#xD;
               -  Serum creatinine no more than 1.5 times ULN or Clearance rate of creatinine &gt;=&#xD;
                  60ml/min;&#xD;
&#xD;
               -  Thyroid stimulating hormone (TSH) &lt;= ULN (T3, T4 levels need to be detected&#xD;
                  simultaneously if abnormalities, the patient can be included if T3, T4 levels is&#xD;
                  normal);&#xD;
&#xD;
               -  LVEF basement &gt;= 50%.&#xD;
&#xD;
          7. Able to swallow tablets.&#xD;
&#xD;
          8. Pregnancy test (serum or urine HCG test within 72h before enrollment) must be negative&#xD;
             in non-surgical sterilization or women of childbearing age, must be not for the&#xD;
             nursing and be willing to take non-pharmacological contraception during treatment&#xD;
             (such as intrauterine device, condom, etc).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of distant metastasis.&#xD;
&#xD;
          2. Bilateral or multiple unilateral breast tumors with different histological&#xD;
             characteristics (such as ER/PR/HER2 status, tumor grade or type, etc).&#xD;
&#xD;
          3. Any invasive malignancy diagnosed within previous 5 years (other than successfully&#xD;
             treated cervical carcinoma in situ, skin basal cell carcinoma or cutaneous squamous&#xD;
             cell carcinoma).&#xD;
&#xD;
          4. Prior radiotherapy, chemotherapy, endocrine therapy, targeted therapy etc.&#xD;
&#xD;
          5. Concurrent use of HRT or any other estrogen-containing medication (including vaginal&#xD;
             estrogens) within 4 weeks.&#xD;
&#xD;
          6. Prior use of estrogen implants.&#xD;
&#xD;
          7. Prior use of high-dose systemic corticosteroids (except as antiemetic treatment),&#xD;
             immunotherapy, or biological response modifiers (e.g., interferon, etc).&#xD;
&#xD;
          8. Use of an unlicensed or other investigational drug within 4 weeks.&#xD;
&#xD;
          9. Any severe comorbidities, inability to give informed consent or unavailability for&#xD;
             follow-up, including but not limited to any of the following:&#xD;
&#xD;
               -  Heart failure above NYHA class 2 level; high-risk uncontrollable arrhythmia;&#xD;
                  unstable angina pectoris; myocardial infarction within 1 year; valvular heart&#xD;
                  disease with clinically significance or requiring intervention.&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease requires treatment.&#xD;
&#xD;
               -  Chronic liver disease (cirrhosis, chronic active hepatitis, etc).&#xD;
&#xD;
               -  Cerebrovascular accident occurred within 6 months.&#xD;
&#xD;
               -  Severe epilepsy or central nervous system diseases.&#xD;
&#xD;
               -  Hypertension which cannot be well controlled by antihypertensive drugs.&#xD;
&#xD;
               -  Abnormal coagulation, bleeding tendency, or receiving thrombolysis or&#xD;
                  anticoagulant therapy.&#xD;
&#xD;
               -  Chronic renal insufficiency.&#xD;
&#xD;
               -  Active infection.&#xD;
&#xD;
               -  Psychiatric disability, etc.&#xD;
&#xD;
         10. Pregnant or nursing females.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shicheng Su, M.D., Ph.D.</last_name>
    <phone>+86 13631304227</phone>
    <email>sushch@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erwei Song, M.D., Ph.D.</last_name>
    <phone>+86 13926477694</phone>
    <email>songew@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shicheng Su, M.D.,Ph.D.</last_name>
      <phone>+86 13631304227</phone>
      <email>sushch@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Erwei Song, M.D.,Ph.D.</last_name>
      <phone>+86 13926477694</phone>
      <email>songew@mail.sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Shicheng Su</investigator_full_name>
    <investigator_title>Director of Shuhua Breast Cancer Research Center of Sun Yat-sen Memorial Hospital</investigator_title>
  </responsible_party>
  <keyword>Hormone receptors-positive breast neoplasms</keyword>
  <keyword>preoperative endocrine therapy</keyword>
  <keyword>Ki-67</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

